UROonco25: New trial data versus real-world practice
“Not only will there be excellent scientific content, but there will also be time dedicated for meaningful discussions between faculty and colleagues on the key data presented, plus the opportunity to reflect how this data fits into your clinical practice,” states Assoc. Prof. Jonathan Aning (GB) in the lead up to next month’s UROonco25 meeting in Seville, Spain (19-21 June).
Organised by the EAU Section of Oncological Urology, UROonco25 brings together a diverse network of experts to explore cutting-edge developments in genitourinary (GU) cancers including prostate (PCa), urothelial, renal cancers, and rare tumours. Read on for some programme highlights.
Thursday, 19 June
The meeting begins at 14:00 CEST with plenary sessions featuring discussions on PCa controversies such as MRI vs PSA, optimal biopsy strategies and extended pelvic lymph node dissection (PLND): still relevant in 2025? In the BCa sessions, discussions will focus on the care for intermediate-risk NMIBC, including the potential for biomarkers to replace flexible cystoscopy in the surveillance of high-grade NMIBC.
Friday, 20 June
The Update Sessions for PCa, BCa and RCC will be a key highlight. These interactive roundtable discussions will feature 1-2 clinical cases for each GU topic, covering everything from diagnosis, localised disease to locally advanced and metastatic stages. Participants will gain key insights into the latest advancements, with a focus on real-world application, and how emerging technologies can be integrated into the care pathway.
For those specialising in rare cancers, Dr. Oscar Brouwer (NL) and Dr. Christian Fankhauser (CH) will chair a session on ‘Advanced penile cancer: Surprising functional results after penile sparing surgery and ideal follow-up protocols’. There will be a case presentation on balancing radical cure and organ-preservation, as well as lectures on ultrasound versus clinical exam during follow-up, and decoding survival expectations: inguinal versus pelvic pN3.
Saturday, 21 June
Chaired by Assoc. Prof. Aning, Prof. Arnulf Stenzl (DE) and Prof. Alessandro Volpe (IT), the ‘Real world urology’ session this year will challenge the EAU Guidelines for diagnosis and active surveillance, treatment and training for localised PCa, and multidisciplinary management of mHSPC/CRPC. Comparing what the guidelines recommend vs what is done in practice, and what is the solution pathfinder?
During the ‘European Urology Oncology‘ session chaired by Prof. Morgan Rouprêt (FR) and Prof. Volpe, the best of onco-urology journals will be shared for prostate cancer, urothelial cancer, rare tumours, and renal cancer. There will also be an award presentation for the best paper published in the European Urology Oncology over the year, with the winning author sharing their article highlights.
The European School of Urology (ESU) has organised a course on “Neoadjuvant and adjuvant treatments in genitourinary tumours”, chaired by Dr. Riccardo Campi (IT), that includes a lecture on the role of perioperative therapies in GU cancers, and a case-based discussion on high-risk localised renal cancer: what would you do?
How to register to attend?
UROonco25 guarantees to be the best place to get critical updates in oncology! Take a look at the extensive scientific programme, and register by 6 June, 2025 (23:59 CEST) to benefit from regular-fee savings.